Status: Recruiting
Study of VIP943 in Subjects With Advanced CD123+ Hematologic Malignancies
Dose Escalation - Determine the maximum tolerated dose (MTD), if possible, or minimum optimal biologic dose (OBD), and evaluate the safety and tolerability of VIP943 in subjects with advanced CD123+ hematologic malignancies
Participants needed: 36
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Vincerx Pharma, Inc.Updated: Nov 15, 2024Locations: 5
Eligibility criteria
Histologically confirmed AML, B-ALL or MDS. Subjects must have exhausted all ava... [+3]
Known central nervous system (CNS) metastases and/or carcinomatous meningitis. [+1]